Hyperlipoproteinemia Type II: all 249 studies

Page 1 of 3. Open to participants first (52), then studies with results posted, then the rest; newest registration first within each.

• EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)Not yet recruitingNCT07894887Phase 1/2
• A Study of SYH2070 Injection in Participants With Mixed HyperlipidemiaRecruitingNCT07695597Phase 2
• Cascade Testing In Identifying At-risk Family Members Of Individuals With Familial Hypercholesterolemia (FH) In PCPNot yet recruitingNCT07653555Not applicable
• An Observational Study to Evaluate Treatment Patterns in High, Very High and Extreme Cardiovascular Risk Patients With Hypercholesterolemia, Including Familial HypercholesterolemiaNot yet recruitingNCT07606118
• A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and AlirocumabRecruitingNCT07543731
• Study of Zodasiran in Adolescent Participants With Homozygous Familial HypercholesterolemiaRecruitingNCT07473843Phase 3
• The ORIGIN-FH StudyRecruitingNCT07470723Not applicable
• QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed DyslipidemiaNot yet recruitingNCT07444086Phase 3
• QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)Not yet recruitingNCT07441317Phase 3
• A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed HyperlipidemiaRecruitingNCT07421297Phase 3
• A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering TherapyNot yet recruitingNCT07421284Phase 3
• Study of ARO-DIMERPA in Adult Participants With Mixed HyperlipidemiaRecruitingNCT07223658Phase 1/2
• Cardiovascular Risk in Children With Chronic Conditions StudyRecruitingNCT07086989
• Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)RecruitingNCT06960902Not applicable
• Computerized Decision Support for Identification and Management of Familial HypercholesterolemiaRecruitingNCT06743659Not applicable
• Assessment of the Prevalence of Steatotic Liver Disease Associated with Metabolic Dysfunction in Patients with Heterozygous Familial HypercholesterolemiaRecruitingNCT06634160
• Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial HypercholesterolemiaRecruitingNCT06597019Phase 3
• Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial HypercholesterolemiaRecruitingNCT06597006Phase 3
• PMMHRI - Familial Hypercholesterolemia RegistryRecruitingNCT06571630
• A Study on Efficacy and Safety of HST101 in Chinese Patients with HypercholesterolemiaRecruitingNCT06568471Phase 3
• Screening for Familial Hypercholesterolemia in ChildrenRecruitingNCT06555120Not applicable
• National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter RegistryRecruitingNCT06546137
• Integrating Whole Genome Sequencing and Digital Twins Into the Management of Hypercholesterolemia in EmiratisRecruitingNCT06535542Not applicable
• Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)RecruitingNCT06461702Early Phase 1
• Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)RecruitingNCT06458010Early Phase 1
• Phase 1b Study of VERVE-201 in Patients With Refractory HyperlipidemiaRecruitingNCT06451770Phase 1
• Atlantic Lipid Lowering Treatment Optimization ProgramRecruitingNCT06439654Not applicable
• Lipid Transport Disorder Italian Genetic Record (LIPIGEN)RecruitingNCT06362473
• Safety and Efficacy Study of NGGT006 in Refractory Hypercholesterolemia PatientsNot yet recruitingNCT06293729Early Phase 1
• A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery DiseaseRecruitingNCT06164730Phase 1
• Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular DiseaseEnrolling by invitationNCT06112327
• EPIRUS FH Reverse Cascade ScreeningNot yet recruitingNCT05825612
• School-based Education and Screening Program With Lipid Screening as a Means to Identify Familial HyperlipidemiaEnrolling by invitationNCT05767996
• Penn Family Screening for Familial HypercholesterolemiaEnrolling by invitationNCT05750667Not applicable
• Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 StudiesRecruitingNCT05682378Phase 3
• Familial Hypercholesterolemia Interpretive Comment - Nudging to Detection.RecruitingNCT05614219Not applicable
• Comparing Direct vs Indirect Methods for Cascade ScreeningRecruitingNCT05348564Not applicable
• Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)Enrolling by invitationNCT05284513Not applicable
• Exosome-based Nanoplatform for Ldlr mRNA Delivery in FHNot yet recruitingNCT05043181Phase 1
• 2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)RecruitingNCT04941599Phase 2
• Evaluation of a Digiphysical Screening Method to Identify and Diagnose Familial HypercholesterolemiaEnrolling by invitationNCT04929457
• Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C ReductionEnrolling by invitationNCT04798430Phase 3
• Child-Parent Familial Hypercholesterolemia ScreeningRecruitingNCT04529967
• Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty AcidsRecruitingNCT04485871Not applicable
• Early Detection of Familial Hypercholesterolemia in ChildrenRecruitingNCT04370899
• Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®RecruitingNCT04313270
• EAS Familial Hypercholesterolaemia Studies CollaborationRecruitingNCT04272697
• PET Imaging of Inflammation and Lipid Lowering StudyRecruitingNCT04073797Not applicable
• The Spanish Familial Hypercholesterolaemia Cohort StudyRecruitingNCT02693548
• Russian Familial Hypercholesterolemia RegistryRecruitingNCT02208869
• Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale CanadaRecruitingNCT02009345
• Study of Awareness and Detection of Familial HypercholesterolemiaRecruitingNCT01960244
• Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying TherapiesCompletedNCT06005597Phase 3Results posted
• A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)CompletedNCT05952869Phase 3Results posted
• A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef LipidsCompletedNCT05952856Phase 3Results posted
• Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.CompletedNCT05425745Phase 3Results posted
• A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)CompletedNCT05261126Phase 2Results posted
• Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying TherapiesCompletedNCT05142722Phase 3Results posted
• Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-CCompletedNCT04666298Phase 2Results posted
• Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial HypercholesterolemiaCompletedNCT04233918Phase 3Results posted
• Evaluating the Efficacy of Pediatric Lipid Screening AlertsCompletedNCT04118348Not applicableResults posted
• A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)CompletedNCT03851705Phase 3Results posted
• Pediatric Reporting of Adult-Onset Genomic ResultsCompletedNCT03832985Early Phase 1Results posted
• Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-CCompletedNCT03814187Phase 3Results posted
• Long Term Safety Study of PRALUENTTerminatedNCT03694197Phase 4Results posted
• An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial HypercholesterolemiaCompletedNCT03510884Phase 3Results posted
• An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial HypercholesterolemiaCompletedNCT03510715Phase 3Results posted
• Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial HypercholesterolemiaCompletedNCT03409744Phase 3Results posted
• Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial HypercholesterolemiaCompletedNCT03403374Phase 4Results posted
• Efficacy and Safety of Evinacumab in Patients With Homozygous Familial HypercholesterolemiaCompletedNCT03399786Phase 3Results posted
• Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)CompletedNCT03397121Phase 3Results posted
• Impact of LDL-cholesterol Lowering on Platelet ActivationTerminatedNCT03331666Phase 4Results posted
• Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)CompletedNCT03156621Phase 3Results posted
• An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High CholesterolCompletedNCT03060577Phase 2Results posted
• A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)CompletedNCT02963311Phase 2Results posted
• An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial HypercholesterolemiaCompletedNCT02890992Phase 2Results posted
• A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)CompletedNCT02748057Phase 3Results posted
• Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)CompletedNCT02722408Phase 2Results posted
• A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)TerminatedNCT02651675Phase 1/2Results posted
• Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)CompletedNCT02624869Phase 3Results posted
• Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)CompletedNCT02597127Phase 2Results posted
• A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)CompletedNCT02460159Phase 3Results posted
• A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial HypercholesterolemiaCompletedNCT02434497Phase 3Results posted
• Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) DisordersCompletedNCT02392559Phase 3Results posted
• Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis TherapyCompletedNCT02326220Phase 3Results posted
• Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)CompletedNCT02265952Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial HypercholesterolemiaCompletedNCT02226198Phase 3Results posted
• Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering TherapyCompletedNCT02173158Phase 3Results posted
• Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)CompletedNCT02107898Phase 3Results posted
• A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial HypercholesterolemiaCompletedNCT01968980Phase 3Results posted
• Gene Analysis and Treatment Optimization in Chinese Homozygous Familial HypercholesterolemiaCompletedNCT01878604Results posted
• Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2CompletedNCT01763918Phase 3Results posted
• Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)CompletedNCT01709500Phase 3Results posted
• Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL DisordersCompletedNCT01624142Phase 2/3Results posted
• Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)CompletedNCT01617655Phase 3Results posted
• A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B GeneCompletedNCT01604824Phase 2Results posted
• Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor AbnormalitiesCompletedNCT01588496Phase 2/3Results posted
• A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)TerminatedNCT01583647Phase 1Results posted
• Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)CompletedNCT01576484Phase 2Results posted
• Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) InhibitorCompletedNCT01556906Phase 2Results posted

← Hyperlipoproteinemia Type II overview